The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.
Study Type
OBSERVATIONAL
Enrollment
1,452
Incidence of Adverse Events (AEs)
The number of patient with any AEs, patients with drug-related AEs
Time frame: Week 52
Systolic Blood Pressure (SBP)
SBP is observed at Week 0 and Week 52. The change of SBP from Week 0 to Week 52 is calculated.
Time frame: Week 0 and Week 52
Diastolic Blood Pressure (DBP)
DBP is observed at Week 0 and Week 52. The change of DBP from Week 0 to Week 52 is calculated.
Time frame: Week 0 and Week 52
Target Blood Pressure Achievement Rate
The proportion of the patients with target blood pressure in 52 weeks administrative period. Target blood pressure is defined as 'Guidelines for the management of hypertension (JSH2009)': less than 140/90 (SBP/DBP) mmHg for \>= 65 years old or cerebrovascular disorder patient; less than 130/80 in diabetes, chronic kidney disease or myocardial infarction patient; less than 130/85 mmHg for others patient.
Time frame: Week 52
Blood Pressure Normalised Rate
The proportion of the patients with normalized blood pressure in 52 weeks on administrative period. Normalized blood pressure is defined less than 140/90 (SBP/DBP) mmHg according to JSH2009
Time frame: Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site 111
Ageo, Japan
Boehringer Ingelheim Investigational Site 209
Aisho-cho, Japan
Boehringer Ingelheim Investigational Site 22
Aizubange-machi, Japan
Boehringer Ingelheim Investigational Site 234
Akashi, Japan
Boehringer Ingelheim Investigational Site 78
Akiruno, Japan
Boehringer Ingelheim Investigational Site 79
Akishima, Japan
Boehringer Ingelheim Investigational Site 235
Akō, Japan
Boehringer Ingelheim Investigational Site 288
Akune, Japan
Boehringer Ingelheim Investigational Site 236
Amagasaki, Japan
Boehringer Ingelheim Investigational Site 237
Amagasaki, Japan
...and 304 more locations